NO984418L - Arylaminokondenserte pyridiner og pyrimidiner - Google Patents
Arylaminokondenserte pyridiner og pyrimidinerInfo
- Publication number
- NO984418L NO984418L NO984418A NO984418A NO984418L NO 984418 L NO984418 L NO 984418L NO 984418 A NO984418 A NO 984418A NO 984418 A NO984418 A NO 984418A NO 984418 L NO984418 L NO 984418L
- Authority
- NO
- Norway
- Prior art keywords
- arylamino
- pyrimidines
- condensed pyridines
- pyridines
- condensed
- Prior art date
Links
- 125000001769 aryl amino group Chemical group 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 abstract 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 abstract 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Luminescent Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1415796P | 1996-03-27 | 1996-03-27 | |
| US64661296A | 1996-05-08 | 1996-05-08 | |
| US3053696P | 1996-10-31 | 1996-10-31 | |
| US3912497P | 1997-02-25 | 1997-02-25 | |
| PCT/US1997/004852 WO1997035539A2 (en) | 1996-03-27 | 1997-03-25 | Arylamino fused pyridines and pyrimidines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO984418D0 NO984418D0 (no) | 1998-09-22 |
| NO984418L true NO984418L (no) | 1998-11-03 |
Family
ID=27486365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO984418A NO984418L (no) | 1996-03-27 | 1998-09-22 | Arylaminokondenserte pyridiner og pyrimidiner |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US6107300A (de) |
| EP (1) | EP0935601A4 (de) |
| JP (1) | JP2002515032A (de) |
| KR (1) | KR20000005037A (de) |
| CN (1) | CN1230184A (de) |
| AU (1) | AU2545897A (de) |
| BR (1) | BR9708261A (de) |
| CA (1) | CA2250241A1 (de) |
| CZ (1) | CZ304098A3 (de) |
| EA (1) | EA199800868A1 (de) |
| EE (1) | EE9800329A (de) |
| HR (1) | HRP970173A2 (de) |
| HU (1) | HUP9902340A3 (de) |
| IL (1) | IL126316A0 (de) |
| LV (1) | LV12262B (de) |
| NO (1) | NO984418L (de) |
| NZ (1) | NZ331874A (de) |
| PL (1) | PL335258A1 (de) |
| SI (1) | SI9720026A (de) |
| SK (1) | SK131798A3 (de) |
| WO (1) | WO1997035539A2 (de) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7296896A (en) | 1995-11-01 | 1997-05-22 | Novartis Ag | Purine derivatives and processes for their preparation |
| EP0968210A1 (de) * | 1997-03-21 | 2000-01-05 | Du Pont Pharmaceuticals Company | Verfahren zur herstellung von triazolopyridinen |
| AU8181098A (en) * | 1997-07-03 | 1999-01-25 | Du Pont Pharmaceuticals Company | Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
| AU2881199A (en) * | 1998-02-26 | 1999-09-15 | Neurogen Corporation | Substituted 1,4-dihydro-4-oxonicotinic carboxamides: gaba brain receptor ligands |
| ES2180338T3 (es) | 1998-11-12 | 2003-02-01 | Neurocrine Biosciences Inc | Antagonistas del receptor de crf y metodos relacionados. |
| PT1129096E (pt) | 1998-11-12 | 2003-09-30 | Neurocrine Biosciences Inc | Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos |
| US6531475B1 (en) | 1998-11-12 | 2003-03-11 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
| GB9903762D0 (en) | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| PL354784A1 (en) | 1999-09-30 | 2004-02-23 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
| AU2583901A (en) * | 1999-12-17 | 2001-06-25 | Ariad Pharmaceuticals, Inc. | Proton pump inhibitors |
| JP2003531111A (ja) * | 1999-12-17 | 2003-10-21 | アライアッド・ファーマシューティカルズ・インコーポレーテッド | プロトンポンプインヒビター |
| AU2001232271A1 (en) * | 2000-02-14 | 2001-08-20 | Japan Tobacco Inc. | Preventives/remedies for postoperative stress |
| WO2002006286A2 (en) * | 2000-07-14 | 2002-01-24 | Bristol-Myers Squibb Pharma Company | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| DE60206363T2 (de) | 2001-02-12 | 2006-07-06 | F. Hoffmann-La Roche Ag | 6-substituierte pyridopyrimidine |
| NZ528207A (en) | 2001-03-13 | 2006-02-24 | Bristol Myers Squibb Pharma Co | 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-A]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| CN1527710A (zh) | 2001-05-14 | 2004-09-08 | ����˹�ж�-����˹˹����ҩƷ��˾ | 作为促肾上腺皮质激素释放因子配体的取代的吡嗪酮、吡啶和嘧啶 |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| WO2003005969A2 (en) | 2001-07-12 | 2003-01-23 | Bristol-Myers Squibb Pharma Company | Tetrahydropurinones as corticotropin releasing factor |
| US7276526B2 (en) | 2001-07-13 | 2007-10-02 | Bristol-Myers Squibb Pharma Company | Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands |
| GB0117525D0 (en) | 2001-07-19 | 2001-09-12 | Procter & Gamble | Solvent welding process |
| GB0117522D0 (en) | 2001-07-19 | 2001-09-12 | Procter & Gamble | Solvent welding process |
| AU2002340405A1 (en) | 2001-11-20 | 2003-06-10 | Bristol-Myers Squibb Pharma Company | 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands |
| US9967633B1 (en) | 2001-12-14 | 2018-05-08 | At&T Intellectual Property I, L.P. | System and method for utilizing television viewing patterns |
| WO2003051881A1 (en) * | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies |
| GB0219746D0 (en) | 2002-08-23 | 2002-10-02 | Inst Of Ex Botany Ascr | Azapurine derivatives |
| SE0301373D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| US20050065171A1 (en) * | 2003-06-25 | 2005-03-24 | Shakespeare William C. | Substituted purine derivatives |
| AU2004272437A1 (en) * | 2003-09-09 | 2005-03-24 | Ono Pharmaceutical Co., Ltd. | CRF antagonists and heterobicyclic compounds |
| EP2210607B1 (de) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamid zur Behandlung von Krebs |
| EP1720877A4 (de) * | 2004-03-02 | 2009-11-04 | Neurogen Corp | Arylsubstituierte purinanaloga |
| EP1598354A1 (de) * | 2004-05-18 | 2005-11-23 | Vasopharm Biotech GmbH | Durch kondensierten zyklus verbundenen n-heteroaryl verbindungen und ihre verwendung als nad(p)h oxidase und blutplättchen-aggregation hemmer |
| US7977345B2 (en) | 2004-07-02 | 2011-07-12 | Exelixis, Inc. | c-MET modulators and method of use |
| US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
| ES2438017T3 (es) * | 2004-07-30 | 2014-01-15 | Methylgene Inc. | Inhibidores de la señalización del receptor del VEGF y del receptor del HGF |
| EP1846410B1 (de) * | 2005-02-10 | 2009-01-21 | Bristol-Myers Squibb Company | Dihydrochinazolinone als 5ht-modulatoren |
| EP1703668A1 (de) * | 2005-03-18 | 2006-09-20 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | System zum Verarbeiten von Dienstleistungs (QoS)-Parametern in einem Kommunikationsnetzwerk |
| AU2006313456B2 (en) * | 2005-05-20 | 2011-06-23 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
| KR101378716B1 (ko) * | 2005-05-20 | 2014-04-10 | 메틸진 인코포레이티드 | Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제 |
| AU2006249866B2 (en) | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| KR20080034171A (ko) * | 2005-07-28 | 2008-04-18 | 브리스톨-마이어스 스큅 컴퍼니 | 세로토닌 수용체 효능제 및 길항제로서의 치환된테트라히드로-1ｈ-피리도[4,3,ｂ]인돌 |
| US7795436B2 (en) * | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
| RU2425834C2 (ru) * | 2005-11-08 | 2011-08-10 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ТИАЗОЛО[4,5-c]ПИРИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРОВ mGluR5 |
| PE20080145A1 (es) * | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| AR060061A1 (es) * | 2006-03-22 | 2008-05-21 | Methylgene Inc | Inhibidores de la actividad de la proteina tirosina quinasa |
| US20080004253A1 (en) * | 2006-06-30 | 2008-01-03 | Bryan James Branstetter | Thiazolopyrimidine modulators of TRPV1 |
| EP2081434A2 (de) | 2006-10-31 | 2009-07-29 | Janssen Pharmaceutica N.V. | Triazolpyrimidinderivate als adp-p2y12-rezeptorantagonisten |
| JP2010508350A (ja) * | 2006-10-31 | 2010-03-18 | ヤンセン ファーマシューティカ エヌ．ベー． | Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体 |
| NZ578096A (en) * | 2007-01-10 | 2011-11-25 | Albany Molecular Res Inc | 5-pyridinone substituted indazoles |
| CN101861311A (zh) * | 2007-07-21 | 2010-10-13 | 阿尔巴尼分子研究公司 | 5-吡啶酮取代的吲唑 |
| WO2009078999A1 (en) | 2007-12-17 | 2009-06-25 | Janssen Pharmaceutica N.V. | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1 |
| NZ588355A (en) * | 2008-03-05 | 2012-03-30 | Methylgene Inc | Inhibitors of protein tyrosine kinase activity |
| US8273900B2 (en) * | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| NZ779754A (en) | 2009-01-16 | 2023-04-28 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| CN117045653A (zh) | 2013-01-23 | 2023-11-14 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| EP3134405B1 (de) | 2014-04-25 | 2019-08-28 | Pfizer Inc | Heteroaromatische verbindungen und deren verwendung als dopamin-d1-liganden |
| CA2976258C (en) * | 2015-02-18 | 2024-02-20 | Buck Institute For Research On Aging | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| US10550085B2 (en) | 2015-08-21 | 2020-02-04 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| WO2017035528A1 (en) * | 2015-08-27 | 2017-03-02 | Nantneuro, Llc | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| WO2019075136A1 (en) | 2017-10-10 | 2019-04-18 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
| CA3103048A1 (en) * | 2018-06-21 | 2019-12-26 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| AU2019319740A1 (en) * | 2018-08-06 | 2021-03-25 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| JP2022530967A (ja) | 2019-05-02 | 2022-07-05 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| WO2020223717A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1544419A (en) * | 1975-11-19 | 1979-04-19 | Science Union & Cie | Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them |
| US4076711A (en) * | 1976-04-05 | 1978-02-28 | Schering Corporation | Triazolo [4,5-d]-pyrimidines |
| EP0155911A1 (de) * | 1984-03-19 | 1985-09-25 | Ciba-Geigy Ag | Purinderivate zur Regulierung des Pflanzenwachstums |
| GB8408615D0 (en) * | 1984-04-04 | 1984-05-16 | Wellcome Found | Heterocyclic compounds |
| US5310731A (en) * | 1984-06-28 | 1994-05-10 | Whitby Research, Inc. | N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents |
| US5175273A (en) * | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
| GB2226027B (en) * | 1988-12-13 | 1992-05-20 | Sandoz Ltd | Adenosine derivatives,their production and use |
| US5063245A (en) * | 1990-03-28 | 1991-11-05 | Nova Pharmaceutical Corporation | Corticotropin-releasing factor antagonism compounds |
| US5240937A (en) * | 1990-04-20 | 1993-08-31 | Burroughs Wellcome Co. | Pharmaceutically active triazolopyridine compounds |
| CA2100863A1 (en) * | 1991-01-23 | 1992-07-24 | David A. Bullough | Adenosine kinase inhibitors |
| US5250679A (en) * | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
| HUT69705A (en) * | 1991-11-25 | 1995-09-28 | Pfizer | Indole derivatives |
| DE69324244T2 (de) * | 1992-01-06 | 1999-09-30 | The Wellcome Foundation Ltd., Greenford | Therapeutische nukleoside der 2',3'-dideoxy-3'-fluor -purin reihe |
| US5424297A (en) * | 1992-04-27 | 1995-06-13 | University Of Virginia Alumni Patents Foundation | Adenosine dextran conjugates |
| TW370529B (en) * | 1992-12-17 | 1999-09-21 | Pfizer | Pyrazolopyrimidines |
| FI964893A7 (fi) * | 1994-06-06 | 1996-12-05 | Pfizer | Substituoituja pyratsoleja, jotka ovat aktiivisia kortikotropiinin vap auttamistekijän (CRF) antagonisteina |
| TW530047B (en) * | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| DK0765327T3 (da) * | 1994-06-16 | 1999-11-29 | Pfizer | Pyrazolo- og pyrrolopyridiner |
| EP0770080B1 (de) * | 1995-05-12 | 1999-07-14 | Neurogen Corporation | Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden |
| PT778277E (pt) * | 1995-12-08 | 2003-11-28 | Pfizer | Derivados heterociclicos substituidos como antagonistas do crf |
-
1997
- 1997-03-21 US US08/823,029 patent/US6107300A/en not_active Expired - Lifetime
- 1997-03-25 CA CA002250241A patent/CA2250241A1/en not_active Abandoned
- 1997-03-25 EP EP97916991A patent/EP0935601A4/de not_active Withdrawn
- 1997-03-25 CN CN97194897A patent/CN1230184A/zh active Pending
- 1997-03-25 EE EE9800329A patent/EE9800329A/xx unknown
- 1997-03-25 HU HU9902340A patent/HUP9902340A3/hu unknown
- 1997-03-25 NZ NZ331874A patent/NZ331874A/xx unknown
- 1997-03-25 PL PL97335258A patent/PL335258A1/xx unknown
- 1997-03-25 JP JP53457797A patent/JP2002515032A/ja active Pending
- 1997-03-25 CZ CZ983040A patent/CZ304098A3/cs unknown
- 1997-03-25 AU AU25458/97A patent/AU2545897A/en not_active Abandoned
- 1997-03-25 KR KR1019980707661A patent/KR20000005037A/ko not_active Withdrawn
- 1997-03-25 IL IL12631697A patent/IL126316A0/xx unknown
- 1997-03-25 BR BR9708261-9A patent/BR9708261A/pt not_active IP Right Cessation
- 1997-03-25 SI SI9720026A patent/SI9720026A/sl not_active IP Right Cessation
- 1997-03-25 EA EA199800868A patent/EA199800868A1/ru unknown
- 1997-03-25 WO PCT/US1997/004852 patent/WO1997035539A2/en not_active Ceased
- 1997-03-25 SK SK1317-98A patent/SK131798A3/sk unknown
- 1997-03-26 HR HR60/039,124A patent/HRP970173A2/hr not_active Application Discontinuation
-
1998
- 1998-09-22 NO NO984418A patent/NO984418L/no unknown
- 1998-10-30 LV LVP-98-195A patent/LV12262B/en unknown
-
2000
- 2000-03-14 US US09/525,619 patent/US6448261B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NO984418D0 (no) | 1998-09-22 |
| US6107300A (en) | 2000-08-22 |
| US6448261B1 (en) | 2002-09-10 |
| NZ331874A (en) | 2000-03-27 |
| EP0935601A4 (de) | 2002-08-07 |
| IL126316A0 (en) | 1999-05-09 |
| HUP9902340A3 (en) | 2001-02-28 |
| EP0935601A2 (de) | 1999-08-18 |
| CA2250241A1 (en) | 1997-10-02 |
| HRP970173A2 (en) | 1999-08-31 |
| SK131798A3 (en) | 2000-05-16 |
| BR9708261A (pt) | 2001-12-04 |
| EA199800868A1 (ru) | 1999-04-29 |
| WO1997035539A3 (en) | 1999-05-14 |
| EE9800329A (et) | 1999-06-15 |
| KR20000005037A (ko) | 2000-01-25 |
| WO1997035539A2 (en) | 1997-10-02 |
| CZ304098A3 (cs) | 1999-02-17 |
| CN1230184A (zh) | 1999-09-29 |
| LV12262B (en) | 1999-10-20 |
| SI9720026A (sl) | 1999-04-30 |
| PL335258A1 (en) | 2000-04-10 |
| AU2545897A (en) | 1997-10-17 |
| LV12262A (lv) | 1999-04-20 |
| JP2002515032A (ja) | 2002-05-21 |
| HUP9902340A2 (hu) | 1999-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO984418L (no) | Arylaminokondenserte pyridiner og pyrimidiner | |
| DK0901374T3 (da) | Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser | |
| DE69328975D1 (de) | Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten | |
| MY115300A (en) | Pyrazolopyrimidines. | |
| ATE50763T1 (de) | Tetralin-derivate, ihre herstellung und verwendung. | |
| GR3032461T3 (en) | Substituted pyrazoles as crf antagonists. | |
| FI931370A0 (fi) | Kvaeve innehaollande analoger av icke-aromatiska heterocykliska foereningar med en fusionerad ring | |
| ATE264846T1 (de) | Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen | |
| CA2118704A1 (en) | Fused Tricyclic Nitrogen Containing Heterocycles as Substance P Receptor Antagonists | |
| TR199902357T2 (xx) | Yeni bile�imler. | |
| PT691128E (pt) | Metodos de administracao de antagonistas de crf | |
| ATE178886T1 (de) | 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten | |
| DE3578063D1 (de) | 1-substituierte tetralinderivate, ihre herstellung und verwendung. | |
| FI822281A0 (fi) | Foerfarande foer framstaellning av pyrimidonderivat | |
| NZ326675A (en) | Oxazoline arthropodicides | |
| TW366262B (en) | Substituted pyridines/pyrimidines, their preparation, and their use as pesticides | |
| ATE102626T1 (de) | Heterocyclische verbindungen, ihre darstellung und verwendung. | |
| BG103271A (en) | Derivatives of n-(benzothiazol-2-yl) piperidine-1-ethaneamines, method for their preparation and application as therapeutical means | |
| TR199901395T2 (xx) | Yeni karboksi ikameli siklik karboksamid t�revleri. | |
| ES8604843A1 (es) | Un metodo para la preparacion de un derivado de acetileno | |
| PH22571A (en) | 4-nitrogen substituted isoquinolinol compounds having cardiotonic, phosphodiesterase fraction iii inhibiting properties and/or renal vasodilating properties | |
| ATE41662T1 (de) | Derivate von dihydro-1h-pyrrolo(1,2-c>imidazol3,5-dion zur aktivierung des wahrnehmungsvermoegens. | |
| DE69210255D1 (de) | THIENOPYRAZIN-2,3-DIONE VERWENDBAR BEI DER BEHANDLUNG VON ZNS-STöRUNGEN, UND IHRE HERSTELLUNG. | |
| DE69015411D1 (de) | 5,11-Dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one und -thione und deren Verwendung bei der Vorbeugung und und Behandlung von AIDS. | |
| EP0401049A3 (de) | Beta-lactam-Elastase-Inhibitoren |